Form 4: Guardant Health CIO Sells 2,000 Shares
Insider Transaction Report
Guardant Health's Chief Information Officer, Kumud Kalia, sold 2,000 shares of common stock for approximately $104.60 per share under a Rule 10b5-1 plan.
Summary
- Kumud Kalia, Chief Information Officer of Guardant Health, Inc. (GH), reported a sale of common stock.
- A total of 2,000 shares of common stock were disposed of on December 8, 2025.
- The shares were sold at a weighted average price of $104.6021 per share, with individual transactions ranging from $104.58 to $104.75.
- Following this transaction, Kumud Kalia directly beneficially owns 22,365 shares of Guardant Health common stock.
- The transaction was made pursuant to a Rule 10b5-1(c) plan, indicating a pre-scheduled sale.
Sentiment
Score: 5
Explanation: The sentiment is neutral. This is a routine insider transaction (sale) executed under a pre-arranged 10b5-1 plan, which typically does not carry significant positive or negative implications for the company's prospects. The amount sold is not exceptionally large relative to the executive's remaining holdings or the company's market capitalization.
Future Outlook
This filing is an insider transaction report and does not contain forward-looking statements or guidance regarding the company's future outlook.
Industry Context
This insider transaction is a routine disclosure for a public company executive and does not inherently reflect broader industry trends or competitive positioning. Insider sales, especially those executed under a Rule 10b5-1 plan, are often pre-scheduled for personal financial planning and are not necessarily indicative of management's view on the company's future performance.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Disclosure of Trading Plan | The transaction was made pursuant to a contract, instruction, or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). | 12/08/2025 | The use of a Rule 10b5-1 plan indicates a pre-scheduled transaction, mitigating concerns about opportunistic insider trading and demonstrating adherence to corporate governance best practices for insider stock transactions. |
Stakeholder Impact
- Shareholders: A minor insider sale, unlikely to have a material impact on shareholder sentiment or the company's stock price. The use of a 10b5-1 plan provides transparency regarding the transaction's pre-planned nature.
Key Dates
| Date | Description |
|---|---|
| 12/08/2025 | Date of transaction (sale of common stock) |
| 12/10/2025 | Date the Form 4 was signed and filed |
Keywords
Guardant Health, GH, Insider Transaction, Form 4, Stock Sale, Kumud Kalia, Chief Information Officer, Rule 10b5-1
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.